Plan robustness evaluation strategies in whole-pelvic proton therapy for high-risk prostate cancer patients within a randomised clinical trial

References

• Dowdell S, Metcalfe P, Morales J, et al. A comparison of proton therapy and IMRT treatment plans for prostate radiotherapy. Australas Phys Eng Sci Med. 2008;31(4):325–331. doi: 10.1007/BF03178602.
   PubMed Web of Science ®Google Scholar
• Widesott L, Pierelli A, Fiorino C, et al. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. Int J Radiat Oncol Biol Phys. 2011;80(5):1589–1600. doi: 10.1016/j.ijrobp.2010.10.005.
   PubMed Web of Science ®Google Scholar
• Schiller KC, Habl G, Combs SE. Protons, photons, and the prostate – is there emerging evidence in the ongoing discussion on particle therapy for the treatment of prostate cancer? Front Oncol. 2016;6:8. doi: 10.3389/fonc.2016.00008.
   PubMed Web of Science ®Google Scholar
• Mottet N, van den Bergh R, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–262. doi: 10.1016/j.eururo.2020.09.042.
   PubMed Web of Science ®Google Scholar
• Murthy V, Maitre P, Kannan S, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39(11):1234–1242. doi: 10.1200/JCO.20.03282.
   PubMed Web of Science ®Google Scholar
• Goitein M. Calculation of the uncertainty in the dose delivered during radiation therapy. Med Phys. 1985;12(5):608–612. doi: 10.1118/1.595762.
   PubMed Web of Science ®Google Scholar
• Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol. 2012;57(11):R99–R117. doi: 10.1088/0031-9155/57/11/R99.
   PubMed Web of Science ®Google Scholar
• Unkelbach J, Alber M, Bangert M, et al. Robust radiotherapy planning. Phys Med Biol. 2018;63(22):22TR02. doi: 10.1088/1361-6560/aae659.
   PubMed Web of Science ®Google Scholar
• Butala AA, Ingram WS, O'Reilly SE, et al. Robust treatment planning in whole pelvis pencil beam scanning proton therapy for prostate cancer. Med Dosim. 2020;45(4):334–338. doi: 10.1016/j.meddos.2020.04.001.
   PubMed Web of Science ®Google Scholar
• Killoran JH, Kooy HM, Gladstone DJ, et al. A numerical simulation of organ motion and daily setup uncertainties: implications for radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37(1):213–221. doi: 10.1016/s0360-3016(96)00477-4.
   PubMed Web of Science ®Google Scholar
• Ong ALK, Ang KW, Master Z, et al. Intensity-modulated radiotherapy for whole pelvis irradiation in prostate cancer: a dosimetric and plan robustness study between photons and protons. Tech Innov Patient Support Radiat Oncol. 2018;6:11–19. doi: 10.1016/j.tipsro.2018.02.001.
   PubMedGoogle Scholar
• Shan J, Sio T, Liu C, et al. A novel and individualized robust optimization method using normalized dose interval volume constraints (NDIVC) for intensity-modulated proton radiotherapy. Med Phys. 2019;46(1):382–393. doi: 10.1002/mp.13276.
   PubMed Web of Science ®Google Scholar
• Busch K, Andersen A, Petersen J, et al. Towards range-guidance in proton therapy to detect organ motion-induced dose degradations. Biomed Phys Eng Express. 2022;8(2):025018. doi: 10.1088/2057-1976/ac5151.
   Web of Science ®Google Scholar
• Lymph node radiation therapy with integrated boost to prostate for high-risk prostate cancer, a randomized phase 3 trial comparing photons vs. protons. 2022. [cited 2023 Feb 14]. https://clinicaltrials.gov/ct2/show/NCT05350475
   Google Scholar
• Tilbæk S, Muren LP, Vestergaard A, et al. Proton therapy planning and image-guidance strategies within a randomized controlled trial for high-risk prostate cancer. Clin Transl Radiat Oncol. 2023;41:100632. doi: 10.1016/j.ctro.2023.100632.
   PubMed Web of Science ®Google Scholar
• Biston MC, Chiavassa S, Grégoire V, et al. Time of PTV is ending, robust optimization comes next. Cancer Radiother. 2020;24(6–7):676–686. doi: 10.1016/j.canrad.2020.06.016.
   PubMed Web of Science ®Google Scholar
• Choo R, Hillman D, Mitchell C, et al. Late toxicity of moderately hypofractionated intensity modulated proton therapy treating the prostate and pelvic lymph nodes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2023;115(5):1085–1094. doi: 10.1016/j.ijrobp.2022.11.027.
   PubMed Web of Science ®Google Scholar
• Szymanski K, Wei J, Dunn R, et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76(5):1245–1250. doi: 10.1016/j.urology.2010.01.027.
   PubMed Web of Science ®Google Scholar
• Skolarus T, Dunn R, Sanda M, et al. Minimally important difference for the expanded prostate cancer index composite short form. Urology. 2015;85(1):101–105. doi: 10.1016/j.urology.2014.08.044.
   PubMed Web of Science ®Google Scholar